Prosecution Insights
Last updated: November 04, 2026
Application No. 18/293,109

MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF

Non-Final OA §102§103§112§DOUBLEPATENT
Filed
Jan 29, 2024
Priority
Jul 30, 2021 — provisional 63/227,834 +2 more
Examiner
MOU, LIYUAN
Art Unit
1628
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Kurome Therapeutics Inc.
OA Round
1 (Non-Final)
44%
Grant Probability
Moderate
1-2
OA Rounds
4m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 44% of resolved cases
44%
Career Allowance Rate
53 granted / 121 resolved
-16.2% vs TC avg
Strong +60% interview lift
Without
With
+59.9%
Interview Lift
resolved cases with interview
Typical timeline
3y 1m
Avg Prosecution
82 currently pending
Career history
215
Total Applications
across all art units

Statute-Specific Performance

§101
1.9%
-38.1% vs TC avg
§103
35.9%
-4.1% vs TC avg
§102
14.0%
-26.0% vs TC avg
§112
25.4%
-14.6% vs TC avg
Black line = Tech Center average estimate • Based on career data from 121 resolved cases

Office Action

§102 §103 §112 §DOUBLEPATENT
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION Election/Restriction Applicant elected without traverse, Group I invention and compound species having structure shown below, on 09/09/2026. PNG media_image1.png 163 212 media_image1.png Greyscale The elected species is a compound of Formula (II) wherein A is CR5, R5 is H, D is N, E is CR3, R3 is H, R' is C1-C7 alkoxy (-OCH3), R2 is cycloalkyl (cyclopropyl), R6 is PNG media_image2.png 114 151 media_image2.png Greyscale , R7 is halogen (F), R8-R12 are each H, m is 1, n is 1, o is 2, and p is 0. Applicant submits claims 1, 3, 17-19, 29, and 35 read on the elected invention and species. Claims 44, 49, 50, 57 and 61 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention. Claims 5-7 and 23-25 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected species, there being no allowable generic or linking claim. The elected species, Compound 24 (See Table 1, CAS# 2899213-06-8, entered STN database on February 24, 2023), is rejected under 35 USC §103 and on the ground of double patenting. To expedite compact prosecution, the search/examination has expanded to non-elected species that are rejected under following 35 USC 102 and 103 section. The absence of other citations of prior art should not be interpreted as an indication that other subgenera within Formula II are free of prior art. Other non-elected species are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a non-elected species. It should be noted that the prior art search will not be extended unnecessarily to cover all non-elected species. Should Applicant overcome the rejection by amending the claim, the amended claim will be reconsidered. The prior art search will be extended to the extent necessary to determine patentability of the Markush-type claim. In the event prior art is found during reconsideration that renders obvious or anticipates the amended Markush-type claim, the claim will be rejected and the action made final. Status of Claims Claims 1, 3, 5-7, 17-19, 23-25, 29, 35, 44, 49, 50, 57 and 61 are pending in the instant application. Claims 5-7, 44, 49, 50, 57 and 61 are withdrawn. Claims 1, 3, 17-19, 29, and 35 are under examination in this office action. Priority The instant application 18/293,109 filed on January 29, 2024, is a national stage of International Application No. PCT/US2022/038902, filed July 29, 2022, which claims priority to U.S. Provisional Application No. 63/227,834, filed July 30, 2021, and U.S. Provisional Application No. 63/289,341, filed December 14, 2021. It’s noted instant elected species, compound 24 is NOT disclosed in Pro’ 834 application. Information Disclosure Statement The reference listed in IDS dated 01/29/2024, 12/19/2025, 03/27/2026 and 08/31/2026 are being considered. Reference written in foreign language is considered to the degree of English abstract or patent family of foreign patent. Drawings The drawings filed on 01/29/2024 are objected to because Figure 1-4 contain plots that are grey shaded and illegible. Corrected drawing sheets in compliance with 37 CFR 1.121(d) are required in reply to the Office action to avoid abandonment of the application. Any amended replacement drawing sheet should include all of the figures appearing on the immediate prior version of the sheet, even if only one figure is being amended. The figure or figure number of an amended drawing should not be labeled as “amended.” If a drawing figure is to be canceled, the appropriate figure must be removed from the replacement sheet, and where necessary, the remaining figures must be renumbered and appropriate changes made to the brief description of the several views of the drawings for consistency. Additional replacement sheets may be necessary to show the renumbering of the remaining figures. Each drawing sheet submitted after the filing date of an application must be labeled in the top margin as either “Replacement Sheet” or “New Sheet” pursuant to 37 CFR 1.121(d). If the changes are not accepted by the examiner, the applicant will be notified and informed of any required corrective action in the next Office action. The objection to the drawings will not be held in abeyance. Claim Objections Claim 35 is objected to because of the following informalities: claim 35 recites “wherein the composition further comprises a formulary ingredient, an adjuvant, or a carrier”. The “formulary ingredient” and “carrier” are repetitive since formulary ingredient include pharmaceutically acceptable carrier. Claim Rejections - 35 USC § 112 The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. Claims 1, 3, 17-18, 29, and 35 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the full-scope of claimed compound of Formula II. This is a written description rejection, rather than an enablement rejection under 35 U.S.C. 112, first paragraph. Applicant is directed to the MPEP 2163 and Guidelines for the Examination of Patent Applications Under the 35 U.S.C. 112, 1st "Written Description" Requirement, Federal Register, Vol. 66, No. 4, pages 1099-1111, Friday January 5, 2001. MPEP 2163.02 states “ Under Vas-Cath, Inc. v. Mahurkar, 935 F.2d 1555, 1563-64, 19 USPQ2d 1111, 1117 (Fed. Cir. 1991), to satisfy the written description requirement, an applicant must convey with reasonable clarity to those skilled in the art that, as of the filing date sought, the inventor was in possession of the invention, and that the invention, in that context, is whatever is now claimed.” Independent claim 1 refers to compound of formula I, II, III with multiple rings substituted with multiple R groups that are further substituted, or a salt, ester, solvate, optical isomer, geometric isomer, salt of an isomer, prodrug, or derivative thereof. Although claims 17 and 18 recite narrower scope of R groups and ring I moiety, the scope of claims 17 and 18 encompassing different combination of L, M, Q, R groups and ring I moiety, and the ester, solvate thereof are not fully supported by instant disclosure. The Applicant is required to provide adequate written description and evidence of possession of the claimed genus, compound of Formula I, II and III and ester, solvate, prodrug, or derivative thereof that aligns with the instantly claimed broad scope. MPEP 2163 II states; “The written description requirement for a claimed genus may be satisfied through sufficient description of a representative number of species by actual reduction to practice (see i)(A) above), reduction to drawings (see i)(B) above), or by disclosure of relevant, identifying characteristics, i.e., structure or other physical and/or chemical properties, by functional characteristics coupled with a known or disclosed correlation between function and structure, or by a combination of such identifying characteristics, sufficient to show the inventor was in possession of the claimed genus (see i)(C) above)”. While applicants are not required to disclose every species encompassed by a genus, the description of the genus is achieved by the recitation of a representative number of species falling within the scope of the claimed genus. “A representative number of species" means that the species which are adequately described are representative of the entire genus. Thus, when there is substantial variation within the genus, one must describe a sufficient variety of species to reflect the variation within the genus” MPEP 2163 II. Instant specification discloses about 84 compounds (See Table 1-8) and activity thereof, wherein compound species exhibit different activity with IC50 ranging from 0.5 nM (Cpd 21) to 447 nM by Cpd 14 against IRAK1 (See Table 9). The disclosed compounds are not representative for the full scope of compound of Formula I, II and III. For example, instant disclosed compounds comprise hydrogen as R3, R4 and R5. Instant specification does not disclose any working example where R3, R4 or R5 are halogen, hydroxy, oxo, —CN, —C(=O)H, —C(=O)OH, C2-C7 alkenyl, C2-C7 alkynyl, -C(=O)NR31R32, cycloalkyl, spiro-fused cycloalkyl, heterocyclyl, aryl, heteroaryl, or fused ring heteroaryl, as recited. Instant specification does not disclose embodiments wherein two of A,D, E are nitrogen. Instant specification does not disclose any working example where R1 or R2 is oxo, C(=O)H, -C(=O)OH, C2-C7 alkenyl, C2-C7 alkynyl,—C(=O)NR31R32, spiro-fused cycloalkyl, or fused ring heteroaryl further substituted with groups as recited. Instant claimed R6 with different combination of m, n, o, p, q, r, s, t, u, v, w, x, are drawn to variety of nitrogen-containing heterocycle substituted with variety of R7 to R30. The R6 group in disclosed working examples are piperidine or pyrrolidine with simple substituent (e.g. F) that do not represent the full scope of R7 to R30 and m to x. Instant specification does not disclose working example wherein R6 is PNG media_image3.png 193 208 media_image3.png Greyscale , or C3-C6 cycloalkyl substitute with one or more NR33R34. The only disclosure of other moieties/groups, in addition to the species reduced to practice, is in the form of general formula with lists of possible groups. This kind of disclosure is not representation of any species. A "laundry list" disclosure of every possible moiety does not constitute a written description of every species in a genus because it would not "reasonably lead" those skilled in the art to any particular species. MPEP 2163.1.A. and Fujikawa v. Wattanasin, 93 ”.3d 1559, 1571, 39 USPQ2d 1895, 1905 (Fed.Cir. 1996). Further, there is no disclosure of working example as ester, solvate or prodrug or derivatives of instantly claimed compounds. There is no disclosure of working example of composition further comprising an adjuvant. As elaborated, there are substantial structural variation exists in the genus/subgenus embraced by instant claims and disclosure of species is not commensurate with the scope of genus/subgenus claimed. One of skill in the art would not recognize from the disclosure that the applicant was in possession of full scope of compound of Formula II. The specification does not clearly allow persons of ordinary skill in the art to recognize that he or she invented what is claimed. The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. Claims 1, 3, 17-18, 29, and 35 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 1 recites compound of I, II or III, wherein R1, R2, R3, R4, and R5 are each independently selected from variety of group/moiety, e.g. H, halogen, hydroxy, oxo, -CN, - C(=O)H, -C(=0)OH, C1-C7 alkyl, C2-C7 alkenyl, C2-C7 alkynyl, C1-C7 alkoxy, -C(=O)NR31R32, cycloalkyl, -O-(C3-C6 cycloalkyl), spiro-fused cycloalkyl, heterocyclyl, aryl, heteroaryl, and fused ring heteroaryl... PNG media_image4.png 78 631 media_image4.png Greyscale ... . A broad range or limitation together with a narrow range or limitation that falls within the broad range or limitation (in the same claim) may be considered indefinite if the resulting claim does not clearly set forth the metes and bounds of the patent protection desired. See MPEP § 2173.05(c). Spiro-fused cycloalkyl is a narrow limitation of cycloalkyl, fused ring heteroaryl is narrow limitation of heteroaryl, and pyrrolyl, piperidyl, piperazinyl, morpholinyl etc. are narrow limitation of heteroaryl, heterocyclyl, aryl, heteroaryl. It’s noted that the definition of other R groups also have similar issues. The claim(s) are considered indefinite because there is a question or doubt as to whether the feature introduced by such narrower language is (a) merely exemplary of the remainder of the claim, and therefore not required, or (b) a required feature of the claims. Claims 1 and 3 recite compounds or prodrug, or derivative thereof. The “prodrug” and “derivative” refer to variety of molecules that have different structures, might be in different recognized chemical classes and have different chemical/physical properties, different pharmaceutical /biological activity and different pharmacokinetic/toxicological profile, etc. An ordinary skilled in the art would not know what compounds/agent are encompassed by "prodrug", thus, the scope of the claim(s) are unascertainable for the patent protection desired. Claims 29 and 35 are rejected due to dependency on claim 1. Further, claim 29 recites compound is an inhibitor of at least one of IRAK1, IRAK4, and FLT3, or wherein the compound is an inhibitor of at least two of IRAK1, IRAK4, and FLT3, or wherein the compound is an inhibitor of IRAK1 and IRAK4, or wherein the compound is an inhibitor of IRAK1, IRAK4, and FLT3. A broad range or limitation together with a narrow range or limitation that falls within the broad range or limitation (in the same claim) may be considered indefinite if the resulting claim does not clearly set forth the metes and bounds of the patent protection desired. See MPEP § 2173.05(c). Recitation of “inhibitor of at least one of IRAK1, IRAK4, and FLT3” is the broad range of limitation compared with “at least two of IRAK1, IRAK4, and FLT3” or “inhibitor of IRAK1, IRAK4 and FLT3”. The following is a quotation of 35 U.S.C. 112(d): (d) REFERENCE IN DEPENDENT FORMS.—Subject to subsection (e), a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. Claim 29 is rejected under 35 U.S.C. 112(d), as being of improper dependent form for failing to further limit the subject matter of the claim upon which it depends, or for failing to include all the limitations of the claim upon which it depends. Claim 29 recites the compound of claim 1 is an inhibitor of IRAK1, IRAK4, and/or FLT3, The biological activity of compound of claim 1 is the intrinsic property of compound of claim 1. Thus, claim 29 reciting intended function/property of compound of claim 1 do not impart any further structural limitation to the compound of claim 1. In order to overcome this ground of rejection, Applicant may wish to (a) cancel the claims, rewrite claim 1 to incorporate the subject matter of claims or present a sufficient showing that the dependent claims comply with the statutory requirements. Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. (a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention. Claims 1 and 3 are rejected under 35 U.S.C. §102 (a)(1) as being anticipated by Compound CAS# 347844-08-9 (entered STN on December 4, 2011, Applicant’s IDS dated 08/31/2026 ). PNG media_image5.png 481 726 media_image5.png Greyscale Compound CAS# 347844-08-9 read on compound of Formula I, wherein, A is CR5, R5 is H, D is N, E is CR3, R3 is H, R1 is H , R2 is C1-C7 alkoxy, R6 is PNG media_image2.png 114 151 media_image2.png Greyscale , R7-R14 are each H, m is 1, n is 1, o is 2, and p is 0. Thus, Compound CAS# 347844-08-9 anticipates instant invention. Claims 1, 3 , 29 and 35 are rejected under 35 U.S.C. §102 (a)(1) and (a)(2) as being anticipated by Eastwood et al. ( WO2011076419 A1, Applicant’s IDS dated 01/29/2024). Eastwood teaches imidazopyridine derivatives, compound of Formula I, as Janus Kinases/JAK inhibitor, pharmaceutical composition comprising aforementioned compound for method of treating disease /disorder (e.g. myeloproliferative disorders, inflammation etc.)( See abstract , page 8, lines 32-37, page 9, lines 15-27; page 15, line 13-14; Examples 1 -186; claims 1-35). PNG media_image6.png 260 338 media_image6.png Greyscale Eastwood teaches compound species, e.g. Example 9, 17, 21 etc. (See page 106, page 115, claim 25) that read on instant claimed compound of Formula I and Formula V, wherein, A is CR5, R5 is H, D is CR4, R4 is H, E is N, R1 is H , R2 is F, R6 is PNG media_image2.png 114 151 media_image2.png Greyscale , R7-R14 are each H, m is 1, n is 1, o is 2, and p is 0. PNG media_image7.png 142 143 media_image7.png Greyscale PNG media_image8.png 131 133 media_image8.png Greyscale PNG media_image9.png 230 244 media_image9.png Greyscale Eastwood is silent that compound of Formula I is inhibitor of IRAK or FLT3. Please note biological activity is the property of compound which does not necessarily add structural limitation/ patentable weight to the compound claims. Eastwood teaches compound species that falls within the scope of instantly claimed compounds, thus, Eastwood anticipates instant invention. Claims 1, 3, 29 and 35 are rejected under 35 U.S.C. §102 (a)(1) and (a)(2) as being anticipated by Wang et al. ( WO2018141002, family member of US 11111245, Applicant’s IDS dated 12/19/2025). Wang teaches 4-(imidazo[1,2-a] pyridine)pyrimidin-2-amine derivatives, compound of Formula I as Cyclin-dependent Kinase (CDK) inhibitors, pharmaceutical composition comprising aforementioned compound and the use thereof for modulating protein kinase activity in a cell and treating cancer (e.g. lung colorectal, etc.)(See abstract, [0008]-[0061], Table 1-2, Examples 1-172, claims 1-16) PNG media_image10.png 201 263 media_image10.png Greyscale PNG media_image11.png 313 794 media_image11.png Greyscale It’s noted A moiety of Wang compound read on instant R6 Wang discloses compound species, e.g. compound 1- 14 ,143, etc. that are encompassed by instant claimed compound of Formula I (See Table 1 ), PNG media_image12.png 107 162 media_image12.png Greyscale PNG media_image13.png 104 201 media_image13.png Greyscale PNG media_image14.png 120 293 media_image14.png Greyscale Wang is silent that compound of Formula I is inhibitor of IRAK or FLT3. Please note biological activity is the property of compound which does not necessarily add structural limitation/ patentable weight to the compound claims. Wang teaches compound species that falls within the scope of instantly claimed compounds, thus, Wang anticipates instant invention. Claims 1, 3, 17-18, 29, and 35 are rejected under 35 U.S.C. §102(a)(1) and (a)(2) as being anticipated by Braganza et al. (US 20110144084, US 8518952, family member of WO 2010016005, JP2011530500, Applicant’s IDS dated 08/31/2026). Braganza discloses substituted 2- heterocyclylamino pyrazine compound of formula I , II, III, or pharmaceutical acceptable salt thereof, as check point kinase I (CHK-1) inhibitors, pharmaceutical composition comprising aforementioned compound and the use thereof for the treatment of disease or condition associated with check point kinase I (CHK-1), e.g. cancers, leukemia (See abstract, [0002]-[0088], [0282], [0379], Table 1, Examples 1-299, claims 1-18 ). PNG media_image15.png 226 218 media_image15.png Greyscale PNG media_image16.png 227 360 media_image16.png Greyscale Braganza discloses A is a heteroaryl selected from a variety of group optionally further substituted with 1-5 Ro (See [0032], [0044], claims 4 and 6-7). PNG media_image17.png 126 245 media_image17.png Greyscale PNG media_image18.png 115 99 media_image18.png Greyscale PNG media_image19.png 114 126 media_image19.png Greyscale PNG media_image20.png 116 99 media_image20.png Greyscale PNG media_image21.png 642 439 media_image21.png Greyscale It’s noted Braganza 2-heterocyclylamino pyrazine read on instant compound wherein D is N, A is CR5, E is CR3. Braganza discloses compound species, e.g. compound 37, 60, 78, 82, 83, etc. that are encompassed by instant claimed compound of Formula I, II, and VI. (See Table 1, Examples 1-299), PNG media_image22.png 244 361 media_image22.png Greyscale PNG media_image23.png 190 345 media_image23.png Greyscale PNG media_image24.png 268 358 media_image24.png Greyscale PNG media_image25.png 181 325 media_image25.png Greyscale PNG media_image26.png 211 341 media_image26.png Greyscale Braganza is silent that compound of Formula I is inhibitor of IRAK or FLT3. Please note biological activity is the property of compound which does not necessarily add structural limitation/ patentable weight to the compound claims. Braganza teaches compound species that falls within the scope of instantly claimed compounds, thus, Braganza anticipates instant invention. Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claims 1, 3, 17-19, 29, and 35 are rejected under 35 U.S.C. §103 as being unpatentable over Hoyt et al. (WO2022132936, hereafter “Hoyt ‘936”, corresponding to US12534469 B2), in view of Patani et al. (Chemical Reviews, 1996. Vol. 96, 8: 3147-3176). The applied reference has a common inventor with the instant application. Based upon the earlier effectively filed date of the reference, it constitutes prior art under 35 U.S.C. 102(a)(2). This rejection under 35 U.S.C. 102(a)(2) might be overcome by: (1) a showing under 37 CFR 1.130(a) that the subject matter disclosed in the reference was obtained directly or indirectly from the inventor or a joint inventor of this application and is thus not prior art in accordance with 35 U.S.C. 102(b)(2)(A); (2) a showing under 37 CFR 1.130(b) of a prior public disclosure under 35 U.S.C. 102(b)(2)(B) if the same invention is not being claimed; or (3) a statement pursuant to 35 U.S.C. 102(b)(2)(C) establishing that, not later than the effective filing date of the claimed invention, the subject matter disclosed in the reference and the claimed invention were either owned by the same person or subject to an obligation of assignment to the same person or subject to a joint research agreement. Hoyt ‘936 discloses multicyclic compound of formula I, II, or ester, solvate, optical isomer, geometric isomer, salt of an isomer, prodrug, or derivative thereof , as IRAK and/or FLT3 inhibitors, pharmaceutical composition comprising aforementioned multicyclic compound and the use thereof for the treatment of IRAK4-mediated disease or condition, e.g. hematopoietic cancers, myelodysplastic syndromes (MDS), acute myeloid leukemia (AML) (See abstract, [0009]-[0014], [00380], Table 1-16 , Examples 1-26, claims 1-77). PNG media_image27.png 342 419 media_image27.png Greyscale PNG media_image28.png 381 814 media_image28.png Greyscale PNG media_image29.png 103 807 media_image29.png Greyscale PNG media_image30.png 371 803 media_image30.png Greyscale PNG media_image31.png 339 684 media_image31.png Greyscale PNG media_image32.png 525 813 media_image32.png Greyscale It’s noted the definition of R groups in Hoyt ‘936 are the same or similar with instant recited R1-R6. Hoyt ‘936 discloses compound species , e.g. Compound 70-86, 96-112, 133- 136, etc. that are similar to instant claimed compounds (See page 16, [0013], [00380], [00484], [00576], Table 1-15; claims 19, 28 and 31) . PNG media_image33.png 224 275 media_image33.png Greyscale PNG media_image34.png 226 306 media_image34.png Greyscale PNG media_image35.png 224 299 media_image35.png Greyscale PNG media_image36.png 228 277 media_image36.png Greyscale PNG media_image37.png 248 278 media_image37.png Greyscale PNG media_image38.png 226 290 media_image38.png Greyscale The difference of Hoyt ‘936 compound and instant compounds is pyridine wherein all A, D and E is CH, versus instant PNG media_image39.png 56 49 media_image39.png Greyscale wherein at least one of A, D, or E is N. Patani teaches bioisosterism for rational modification of lead compounds. Patani teaches a group of bioisosteres elicit similar biological activity as either classical or nonclassical, wherein the classical bioisosteres are a series of replacements defined by Grimm’s Hydride Displacement Law and Erlenmeyer’s definition of isosteres (See p. 3148-3149). PNG media_image40.png 106 404 media_image40.png Greyscale Patani teaches modifications of classical isosteres involving fluorine, hydroxyl, amino, and methyl group interchanges (See page 3150-3152). Patani also teaches modifications of classical isosteres in the ring, wherein CH, O, N are modified as divalent or trivalent ring equivalent (See page 3158-3160). It’s noted instant recited A, D, E is N or CR further attests bioisosterism between =CH and =N. According to MPEP § 2144.09, A prima facie case of obviousness may be made when chemical compounds have very close structural similarities and similar utilities. "An obviousness rejection based on similarity in chemical structure and function entails the motivation of one skilled in the art to make a claimed compound, in the expectation that compounds similar in structure will have similar properties." In re Payne, 606 F.2d 303, 313, 203 USPQ 245, 254 (CCPA 1979). It would have been prima facie obvious to one of ordinary skill in the art before the effective filing date of instant application to explore alternative IRAK and/or FLT inhibitor based on the collective teachings of Hoyt ‘936, together with experimentation/optimization based on general knowledge of structure similarity and bioisosteric modification as taught by Patani. A skilled artisan would be motivated to do so and reasonably expect the bioisosteric replacement of =CH with =N on pyridine ring would provide alternative compounds that exhibit activity against IRAK. For example, Hoyt ‘936 compound 102 could have been modified from pyridine ring to pyridazine ring and arrive at instant elected species. PNG media_image41.png 307 683 media_image41.png Greyscale One of ordinary skill in the art would have had reasonable expectation of success in producing the claimed invention based on the combined teachings of prior art and general knowledge of structure similarity and bioisosteric modification. Therefore, the invention as a whole is prima facie obvious to one of ordinary skill in the art before the effective filing date of the claimed invention, as evidenced by the references, especially in the absence of evidence to the contrary. Claims 1,3, 17-19, 29 and 35 are rejected under 35 U.S.C. 103 as being unpatentable over Starczynowski et al. (WO2018038988, hereafter “Starczynowski’ 988”, Applicant’s IDS dated 12/19/2025 ), in view of Patani et al. (Chemical Reviews, 1996. Vol. 96, 8: 3147-3176). Starczynowski’ 988 discloses compound of formula I, II, or salt or isomer or derivative thereof , as IRAK and/or FLT3 inhibitors, pharmaceutical composition comprising aforementioned multicyclic compound and the use thereof for the treatment of IRAK4-mediated disease or condition, e.g. cancers, (See abstract, [0005]-[0013], [0053], [0062], Table 1, page 112-117, [00242], Table 1-2, claims 1-67). PNG media_image42.png 392 452 media_image42.png Greyscale PNG media_image43.png 239 775 media_image43.png Greyscale PNG media_image44.png 345 757 media_image44.png Greyscale PNG media_image45.png 296 782 media_image45.png Greyscale ... PNG media_image46.png 668 781 media_image46.png Greyscale Starczynowski’ 988 embodiments comprising R7 attached to Y is NH read on instant R6. Starczynowski’ 988 discloses compound species , e.g. Compound I-3, I-18, I-21, I-29 , etc. that are similar to instant claimed compounds (See Table 1-15; claims 19, 28 and 31) . PNG media_image47.png 233 453 media_image47.png Greyscale PNG media_image48.png 200 423 media_image48.png Greyscale The major difference of Starczynowski’ 988 compound and instant compounds is CH vs N on the rings which are bioisosteres as taught by Patani as elaborated in preceding 103 rejection. It’s noted instant recited A, D, E is N or CR further attests bioisosterism between =CH and =N. According to MPEP § 2144.09, A prima facie case of obviousness may be made when chemical compounds have very close structural similarities and similar utilities. "An obviousness rejection based on similarity in chemical structure and function entails the motivation of one skilled in the art to make a claimed compound, in the expectation that compounds similar in structure will have similar properties." In re Payne, 606 F.2d 303, 313, 203 USPQ 245, 254 (CCPA 1979). It would have been prima facie obvious to one of ordinary skill in the art before the effective filing date of instant application to explore alternative IRAK and/or FLT inhibitor based on the collective teachings of Starczynowski’ 988 and general knowledge of structure similarity and bioisosteric modification as taught by Patani. A skilled artisan would be motivated to do so and reasonably expect the bioisosteric replacement of =CH with nitrogen on the rings would provide alternative compounds that exhibit activity against IRAK. One of ordinary skill in the art would have had reasonable expectation of success in producing the claimed invention based on the combined teachings of prior art and general knowledge of structure similarity and bioisosteric modification. Therefore, the invention as a whole is prima facie obvious to one of ordinary skill in the art before the effective filing date of the claimed invention, as evidenced by the references, especially in the absence of evidence to the contrary. Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. Claims 1, 3, 17-19, 29, and 35 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-20 of U.S. Patent No. 12534469, in view of Patani et al. (Chemical Reviews, 1996. Vol. 96, 8: 3147-3176). Reference claims are drawn to a compound of Formula I or salt, ester, solvate, optical isomer, geometric isomer, salt of an isomer, prodrug, or derivative thereof. PNG media_image49.png 149 175 media_image49.png Greyscale The definition of R groups in reference claims are the same or similar with instant recited R1-R6. For example, R6 is PNG media_image50.png 140 176 media_image50.png Greyscale PNG media_image51.png 183 181 media_image51.png Greyscale Reference claims 4 and 7 recite compounds that are similar to instant claimed compounds PNG media_image33.png 224 275 media_image33.png Greyscale PNG media_image52.png 244 298 media_image52.png Greyscale PNG media_image34.png 226 306 media_image34.png Greyscale PNG media_image35.png 224 299 media_image35.png Greyscale PNG media_image37.png 248 278 media_image37.png Greyscale PNG media_image38.png 226 290 media_image38.png Greyscale The difference of reference compound and instant compounds are CH on pyridine vs N on pyrazine or pyrimidine which are bioisosteres as taught by Patani as elaborated in preceding 103 rejection. It’s noted instant recited A, D, E is N or CR further attests bioisosterism between =CH and =N. PNG media_image41.png 307 683 media_image41.png Greyscale According to MPEP § 2144.09, A prima facie case of obviousness may be made when chemical compounds have very close structural similarities and similar utilities. "An obviousness rejection based on similarity in chemical structure and function entails the motivation of one skilled in the art to make a claimed compound, in the expectation that compounds similar in structure will have similar properties." In re Payne, 606 F.2d 303, 313, 203 USPQ 245, 254 (CCPA 1979). The instant application shares at least one common inventor/applicant/assignee with reference patent. Based on the continuing data on the record, instant application is not related to the reference patent, thus no 35 USC 121 shield exists. Claims 1, 3, 17-18, 29 and 35 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-37 of U.S. Patent No. 11254667, in view of Patani et al. (Chemical Reviews, 1996. Vol. 96, 8: 3147-3176). Reference claims are drawn to a compound of Formula I or salt, or stereoisomer thereof, as IRAK and/or FLT inhibitor. PNG media_image53.png 238 270 media_image53.png Greyscale PNG media_image54.png 195 487 media_image54.png Greyscale Reference compounds comprising R7 attached to Y is NH read on instant R6. The definition of R1, R2, R4, R5, R6 group in reference compounds are similar with instant recited R group, respectively, Reference claim 23 recites compound species that are similar to instant claimed compounds. PNG media_image55.png 154 266 media_image55.png Greyscale PNG media_image56.png 130 254 media_image56.png Greyscale The main difference of reference compound and instant compounds is CH vs N on the rings which are bioisosteres as taught by Patani as elaborated in preceding 103 rejection. It’s noted instant recited A, D, E is N or CR further attests bioisosterism between =CH and =N. According to MPEP § 2144.09, A prima facie case of obviousness may be made when chemical compounds have very close structural similarities and similar utilities. "An obviousness rejection based on similarity in chemical structure and function entails the motivation of one skilled in the art to make a claimed compound, in the expectation that compounds similar in structure will have similar properties." In re Payne, 606 F.2d 303, 313, 203 USPQ 245, 254 (CCPA 1979). The instant application shares at least one common inventor/applicant/assignee with reference patent. Based on the continuing data on the record, instant application is not related to the reference patent, thus no 35 USC 121 shield exists. Claims 1, 3, 17-19, 29 and 35 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1- 20 of U.S. Patent No. 12612410 , in view of Patani et al. (Chemical Reviews, 1996. Vol. 96, 8: 3147-3176). Reference claims are drawn to a compound of Formula I or salt, ester, solvate, optical isomer, geometric isomer, salt of an isomer, prodrug, or derivative thereof, as IRAK or FLT3 inhibitor. PNG media_image57.png 152 187 media_image57.png Greyscale The definition of R group in reference compounds are similar with instant recited R group, respectively. Reference claims 4 and 7 recite compound species that are similar to instant claimed compounds PNG media_image58.png 166 196 media_image58.png Greyscale PNG media_image59.png 164 200 media_image59.png Greyscale PNG media_image60.png 177 202 media_image60.png Greyscale The main difference of reference compound and instant compounds is CH vs N on the rings which are bioisosteres as taught by Patani as elaborated in preceding 103 rejection. It’s noted instant recited A, D, E is N or CR further attests bioisosterism between =CH and =N. According to MPEP § 2144.09, A prima facie case of obviousness may be made when chemical compounds have very close structural similarities and similar utilities. "An obviousness rejection based on similarity in chemical structure and function entails the motivation of one skilled in the art to make a claimed compound, in the expectation that compounds similar in structure will have similar properties." In re Payne, 606 F.2d 303, 313, 203 USPQ 245, 254 (CCPA 1979). The instant application shares at least one common inventor/applicant/assignee with reference patent. Based on the continuing data on the record, instant application is not related to the reference patent, thus no 35 USC 121 shield exists. Claims 1, 3, 17-19, 29 and 35 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1,3, 6, 11, 14-15,18, 27, 29, 43, 49-51 and 55-57 of copending U.S. Patent application No. 18/018, 742 , in view of Patani et al. (Chemical Reviews, 1996. Vol. 96, 8: 3147-3176). Reference claims are drawn to a compound of Formula I or salt, ester, solvate, optical isomer, geometric isomer, salt of an isomer, prodrug, or derivative thereof, as IRAK or FLT3 inhibitor. PNG media_image57.png 152 187 media_image57.png Greyscale The definition of R group in reference compounds are similar with instant recited R group, respectively. Reference claims 6, 14, 18 recite compound species that are similar to instant claimed compounds. PNG media_image61.png 136 164 media_image61.png Greyscale PNG media_image62.png 148 171 media_image62.png Greyscale The main difference of reference compound and instant compounds is CH vs N on the rings which are bioisosteres as taught by Patani as elaborated in preceding 103 rejection. It’s noted instant recited A, D, E is N or CR further attests bioisosterism between =CH and =N. According to MPEP § 2144.09, A prima facie case of obviousness may be made when chemical compounds have very close structural similarities and similar utilities. "An obviousness rejection based on similarity in chemical structure and function entails the motivation of one skilled in the art to make a claimed compound, in the expectation that compounds similar in structure will have similar properties." In re Payne, 606 F.2d 303, 313, 203 USPQ 245, 254 (CCPA 1979). The instant application shares at least one common inventor/applicant/assignee with reference patent. Based on the continuing data on the record, instant application is not related to the reference patent, thus no 35 USC 121 shield exists. Claims 1, 3, 17-19, 29 and 35 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-11, 13, 19, 23 and 27 of copending U.S. Patent application No. 18/874, 609, in view of Patani et al. (Chemical Reviews, 1996. Vol. 96, 8: 3147-3176). Reference claims are drawn to a compound of Formula I or salt, ester, solvate, optical isomer, geometric isomer, salt of an isomer, prodrug, or derivative thereof, as IRAK or FLT3 inhibitor. PNG media_image57.png 152 187 media_image57.png Greyscale The definition of R group in reference compounds are similar with instant recited R group, respectively. Reference claims 4 and 11 recite compound species that are similar to instant claimed compounds. PNG media_image63.png 129 188 media_image63.png Greyscale The main difference of reference compound and instant compounds is CH vs N on the rings which are bioisosteres as taught by Patani as elaborated in preceding 103 rejection. It’s noted instant recited A, D, E is N or CR further attests bioisosterism between =CH and =N. According to MPEP § 2144.09, A prima facie case of obviousness may be made when chemical compounds have very close structural similarities and similar utilities. "An obviousness rejection based on similarity in chemical structure and function entails the motivation of one skilled in the art to make a claimed compound, in the expectation that compounds similar in structure will have similar properties." In re Payne, 606 F.2d 303, 313, 203 USPQ 245, 254 (CCPA 1979). The instant application shares at least one common inventor/applicant/assignee with reference patent. Based on the continuing data on the record, instant application is not related to the reference patent, thus no 35 USC 121 shield exists. Conclusion No claims are allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to LIYUAN MOU whose telephone number is (571)270-1791. The examiner can normally be reached Mon-Fri 9:00-5:30. Examiner interviews are available via telephone, in-person, and video using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Amy L Clark can be reached on (571)272-1310. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /LIYUAN MOU/Examiner, Art Unit 1628 /JARED BARSKY/Primary Examiner, Art Unit 1628
Read full office action

Prosecution Timeline

Jan 29, 2024
Application Filed
Oct 30, 2026
Non-Final Rejection mailed — §102, §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12767675
STRUCTURED MOLECULAR VECTORS FOR ANTI-INFLAMMATORY COMPOUNDS AND USES THEREOF
5y 2m to grant Granted Oct 20, 2026
Patent 12758544
New Pharmaceutical Formulation
4y 8m to grant Granted Oct 13, 2026
Patent 12758487
METHODS FOR DOSE INITIATION OF ARIPIPRAZOLE TREATMENTS
2y 4m to grant Granted Oct 13, 2026
Patent 12708604
Lyophilized preparation of prostaglandin E1 methyl ester for injection and production and use thereof
5y 2m to grant Granted Aug 18, 2026
Patent 12692254
BENZIMIDAZOLE INHIBITORS OF PAD ENZYMES
5y 5m to grant Granted Jul 28, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
44%
Grant Probability
99%
With Interview (+59.9%)
3y 1m (~4m remaining)
Median Time to Grant
Low
PTA Risk
Based on 121 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month